## CDK12-IN-3

| Cat. No.:          | HY-112261   |       |         |  |  |
|--------------------|---|-------|---------|--|--|
| CAS No.:           | 2220184-50-7  |       |         |  |  |
| Molecular Formula: | C <sub>23</sub> H <sub>28</sub> F <sub>2</sub> N <sub>8</sub> O |       |         |  |  |
| Molecular Weight:  | 470.52  |       |         |  |  |
| Target:            | CDK   |       |         |  |  |
| Pathway:           | Cell Cycle/DNA Damage   |       |         |  |  |
| Storage:           | Powder  | -20°C | 3 years |  |  |
|                    |   | 4°C   | 2 years |  |  |
|                    | In solvent  | -80°C | 2 years |  |  |
|                    |   | -20°C | 1 year  |  |  |
|                    |   |       |         |  |  |

®

MedChemExpress

## SOLVENT & SOLUBILITY

|        |   | Mass<br>Solvent<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|--------|---|----------------------------------|-----------|------------|------------|
|        | Preparing<br>Stock Solutions  | 1 mM                             | 2.1253 mL | 10.6265 mL | 21.2531 mL |
|        |   | 5 mM                             | 0.4251 mL | 2.1253 mL  | 4.2506 mL  |
|        |   | 10 mM                            | 0.2125 mL | 1.0627 mL  | 2.1253 mL  |
|        | Please refer to the solubility information to select the appropriate solvent.                 |                                  |           |            |            |
| n Vivo | <ol> <li>Add each solvent of<br/>Solubility: ≥ 2.33 n</li> <li>Add each solvent of</li> </ol> | 0 >> 45% saline                  |           |            |            |

| BIOLOGICAL ACTIVITY       |   |  |  |  |
|---------------------------|---|--|--|--|
| Description               | CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC <sub>50</sub> of 491 nM in enzymatic assay.   |  |  |  |
| IC <sub>50</sub> & Target | CDK12<br>491 nM (IC <sub>50</sub> )   |  |  |  |
| In Vitro                  | CDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain of RNA Pol II as well as growth inhibition of OV90 cells and acute cytotoxicity to THP1 cells. <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |  |  |  |

HO

## REFERENCES

[1]. Johannes JW, et al. Structure-Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem. 2018 Feb 6;13(3):231-235.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA